Press

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

Nov 3 • 8 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that The New England Journal of Medicine (NEJM), the world’s leading peer-reviewed medical journal, has published the positive results from its phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) – the largest study…

Silo Wellness Breaking News: Jackson County Oregon’s Proposed TPM Restrictions Put Rural Psilocybin Retreat Therapy Centers at Risk

Nov 3 • 3 min read

Silo Wellness Inc. (CSE: SILO | OTCQB: SILFF | FSE: 3K7A), Oregon’s only publicly traded psychedelics company, announces that the Jackson County Planning Commission has proposed to amend the Jackson County Development Ordinance “to add Psilocybin Time, Place, and Manner Restrictions” (TPM) in the event that the BM 109 opt-out vote is unsuccessful next week. The…

Revitalist Releases Supplement Line to Enhance the Results of Psychedelic Medicines

Nov 2 • 2 min read

Revitalist Lifestyle and Wellness LTD. (CSE: CALM | OTCQB: RVLWF | FSE: 4DO), releases proprietary supplement lines to extend the results of psychedelic medicine outcomes. Through a proprietary blend of vitamins, anti-inflammatories and known cognitive enhancing ingredients, Revive+ and Restore+ have been formulated to enhance psychedelic therapy. “Providing a comprehensive wellness offering to our clients…

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Nov 2 • 2 min read

PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration (USFDA) in advance of its pre-IND meeting scheduled for later this month. PharmAla will be requesting FDA feedback on the nonclinical and CMC development plan to support the initial clinical trial for…

Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders

Nov 2 • 4 min read

Lusaris Therapeutics, a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological conditions, launched today with a $60 million Series A financing. The company’s lead program, LSR-1019, is a best-in-class sublingual formulation of 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a fast-acting and rapidly clearing serotonergic psychedelic, in development for patients with treatment-resistant depression (TRD) and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435